pharma& to Highlight Efficacy and Safety Data for Rucaparib in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

Intended for the healthcare media

Vienna, Austria, June 5, 2025 – pharmaand GmbH (pharma&), a global company dedicated to preserving the availability and fostering the further development of essential medicines to leave no patient behind, today announced long-term data for rucaparib in advanced ovarian cancer will be presented in a mini-oral session during the **ESMO Gynaecological Cancers Congress 2025** June 19-21 in Vienna, Austria.

> **Mini-Oral Title:** Efficacy and Safety of Rucaparib Maintenance Treatment in Patients from ATHENA-MONO/GOG-3020/ENGOT-ov45 with Newly Diagnosed Advanced Ovarian Cancer not Associated with Homologous Recombination Deficiency
> **Presenter**: Professor Vanda Salutari, MD, Department of Health of Woman and Child, Catholic University of Sacred Heart, Rome, Italy
> **Date and Time:** 10:45 a.m. CET, Friday, June 20
> **Location:** Hall D

Congress attendees can visit pharma& at its booth, 01, in Hall X1.

About the ATHENA Clinical Trial
ATHENA (GOG 3020/ENGOT-ov45) (NCT03522246) is an international, randomized, double-blind, phase III trial consisting of two separate and fully independently powered study comparisons evaluating rucaparib monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment for patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. ATHENA enrolled approximately 1000 patients across 24 countries, all women with newly diagnosed ovarian cancer who responded to their first-line chemotherapy. The trial completed accrual in 2020 and was conducted in association with the GOG Foundation, Inc. (GOG-F) in the U.S. and the European Network of Gynaecological Oncological Trial groups (ENGOT) in Europe. GOG-F and ENGOT are the two largest cooperative groups in the U.S. and Europe dedicated to the treatment of gynecological cancers.

ATHENA-MONO is evaluating the benefit of rucaparib monotherapy versus placebo in 538 women in this patient population. The primary efficacy analysis evaluated two prospectively defined molecular sub-groups in a step-down manner: 1) HRD-positive (inclusive of BRCA mutant) tumors, and 2) the intent-to-treat population, or all patients treated in ATHENA-MONO.

###

About pharma& (pharmaand.com)

pharmaand GmbH (pharma&), a privately owned global company headquartered in Austria, Vienna, aspires to breathe new life into proven medicines through an agile and fully integrated business model, and aims to guarantee the enduring availability, dependability, and quality of essential drugs worldwide that patients and healthcare providers rely on. Over the past five years, pharma& has acquired and integrated 10+ medicines, expanding its portfolio across a wide range of therapy areas, with an increasing focus on hematology and oncology treatments. The Company's unique synthesis of subsidiaries, joint ventures, and partners enables pharma& to provide its portfolio of medicines to eligible patients worldwide by spanning the continuum of development, product and API manufacturing, partner distribution, healthcare provider engagement, distribution, and services to patients.

# # #

pharma& Media Contact:
media@pharmaand.com